Table 3.
Association between final HER2 status and the clinico-pathological parameters of pure DCIS cohort
| Parameter | HER2 status | |||
|---|---|---|---|---|
| Total (n = 646) n (%) | Positive (n = 128) n (%) | Negative (n = 518) n (%) | χ2 (p value) | |
| Age (years)* | ||||
| Less than 40 | 22 (3.4) | 7 (6) | 15 (3) | 2.12 |
| Between 40 and 60 | 376 (58.2) | 74 (58) | 302 (58) | (0.347) |
| More than 60 | 248 (38.4) | 47 (36) | 201 (39) | |
| Presentation | ||||
| Screening | 336 (52) | 69 (54) | 267 (51) | 0.23 |
| Symptomatic | 310 (48) | 59 (46) | 251 (49) | (0.632) |
| DCIS size (mm) | ||||
| Less than 16 | 223 (34.8) | 27 (22) | 196 (38) | 20.63 |
| Between 16 and 40 | 247 (38.5) | 47 (37) | 200 (39) | (<0.0001) |
| More than 40 | 171 (26.7) | 52 (41) | 119 (23) | |
| Nuclear grade | ||||
| Low | 87 (13.5) | 0 (0) | 87 (17) | 58.58 |
| Intermediate | 166 (25.7) | 13 (10) | 153 (29) | (<0.0001) |
| High | 393 (60.8) | 115 (90) | 278 (54) | |
| Comedo necrosis | ||||
| Yes | 411 (63.8) | 111 (87) | 300 (58) | 36.28 |
| No | 233 (36.2) | 17 (13) | 216 (42) | (<0.0001) |
| Management | ||||
| Mastectomy | 339 (52.5) | 84 (66) | 255 (49) | 11.06 |
| Breast conserving surgery | 307 (47.5) | 44 (34) | 263 (51) | (0.001) |
| Radiotherapy | ||||
| Yes | 95 (14.7) | 19 (15) | 76 (15) | 0.002 |
| No | 551 (85.3) | 109 (85) | 442 (85) | (0.961) |
| Oestrogen receptor status | ||||
| Positive | 426 (75.3) | 45 (40) | 381 (84) | 88.86 |
| Negative | 140 (24.7) | 66 (60) | 74 (16) | (<0.0001) |
| Progesterone receptor status | ||||
| Positive | 302 (46.7) | 18 (14) | 284 (55) | 68.51 |
| Negative | 344 (53.3) | 110 (86) | 234 (45) | (<0.0001) |
| Ki67 index | ||||
| High proliferative | 108 (23.0) | 64 (59) | 97 (27) | 37.46 |
| Low proliferative | 361 (77.0) | 45 (41) | 263 (73) | (<0.0001) |
p value in bold: significant
DCIS Ductal carcinoma in situ, n number
*Age: categorised according to the Van Nuys Prognostic Index (VNPI)